Navigation Links
Telik Announces First Quarter 2013 Financial Results
Date:5/10/2013

PALO ALTO, Calif., May 10, 2013 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2013.  The net loss for the quarter ended March 31, 2013 was $1.9 million, or $0.46 per share, compared with a net loss of $2.3 million, or $1.25 per share, for the same period in 2012. 

Total research and development expenses (R&D) in the first quarter of 2013 were $0.8 million, compared to $1.0 million for the same period in 2012.  The decrease in R&D expenses was primarily due to lower headcount and related costs, and lower clinical development expenditures as a result of cost reduction efforts.

Total general and administrative expenses (G&A) in the first quarter of 2013 were $1.2 million, compared to $1.3 million for the same period in 2012.  The decrease in G&A expenses was primarily due to lower headcount and related expenses, and lower administrative expenses as a result of cost reduction efforts.

Telik is currently focusing on the clinical development of its lead product candidate, TELINTRA® for Myelodysplastic Syndrome (MDS) and other blood disorders. The design of the company's randomized placebo-controlled Phase 3 registration trial of TELINTRA for the treatment of low to intermediate-1 risk MDS using red-blood-cell transfusion independence as the primary endpoint, in accordance with the FDA's guidance, has been completed.  In order to initiate the registration trial, the company is currently looking to secure funding through the establishment of a corporate partnership, funding from a non-profit agency, or other financing sources. 

As of March 31, 2013, cash, cash equivalents and investments totaled $5.6 million, compared with $5.0 million for the quarter ended December 31, 2012.&#
'/>"/>

SOURCE Telik, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
2. Telik Announces Third Quarter 2012 Financial Results
3. Telik Announces Fourth Quarter And 2012 Year End Financial Results And 2013 Financial Guidance
4. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
5. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
6. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
7. Misonix Announces New Distribution Agreement For Panama
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Quebec , March 27, 2015  Valeant Pharmaceuticals ... today the closing of its previously announced registered offering ... (the "Offering"). Pursuant to the Offering, the ... $199.00 per share, for aggregate gross proceeds of approximately ... with the U.S. Securities and Exchange Commission a final ...
(Date:3/27/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... announced that they have entered into an ... proprietary sd-rxRNA® technology for use in developing ... the potential to result in novel, more ... could be a significant step toward personalized ...
(Date:3/27/2015)... , March 27, 2015  WebMD Health ... source of health information, today announced an ... National Action Plan for Combating Antibiotic-Resistant ... emphasized the urgency and importance of addressing ... and global health.    The WebMD ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3
... Calif., Aug. 12 Founder of the Dermatology Institute, Peter Rullan, ... Perfect™ treatments to his patients with the purchase of the ... excited to add this new service for our patients," Dr. Rullan ... wanted to find a system that not only met my patients, ...
... PDL BioPharma, Inc. (PDL) (Nasdaq: www.pdl.com . ... logo are considered trademarks of PDL BioPharma, Inc. ... release contains forward-looking statements. Each of these forward-looking statements ... from those, express or implied, in these forward-looking statements. ...
Cached Medicine Technology:Chula Vista's Dr. Peter Rullan Adds Alma Lasers' Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients 2PDL BioPharma Receives Letter from Genentech Relating to European Patents 2
(Date:3/28/2015)... 2015 Lately the student-athlete experience ... changes and proposals around the NCAA. In a March ... collegiate student-athletes across a spectrum of universities and sports ... challenges. The special panel consists of athletes who have ... from football, track and field, baseball, and volleyball. They ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 The ... method of sustainable health. After 18 years of research ... including professional UFC contenders, Dr. Jon Petrick is excited ... , Just some of the immediate benefits of this ... vitality, increased levels of strength of the immune system, ...
(Date:3/28/2015)... March 28, 2015 Purity Products®, ... supplements announces the release of their revolutionary new ... in two randomized, double-blind, placebo-controlled clinical studies to ... and hip size. MuffinStop™ is a combination of ... Garcinia mangostana, fused together to create one of ...
(Date:3/27/2015)... The Monogamy Method - ... Sanderson and Jason Rogers has just been released to ... The commotion surrounding the course's launch has caught the ... an in-depth review of the new program. , "Many ... their lives suddenly start pulling away or expressing interest ...
(Date:3/27/2015)... Florida Hospital is excited to continue its partnership ... care provider for the 2015 and 2016 season. As the ... and an athletic trainer for the team throughout each season. ... against the Cleveland Gladiators at Amalie Arena; the game starts ... to us as it gives us the opportunity, to provide ...
Breaking Medicine News(10 mins):Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3
... Novavax Inc. (Nasdaq: NVAX) announced ... 12.5 million shares of Novavax,s common stock at $0.88 per share ... the new strategic alliance between Novavax and Cadila. Novavax intends to ... pay a portion of its 4.75% senior convertible notes due in ...
... that it reduces replication of the virus, , , WEDNESDAY, ... help people with HIV who don,t respond to standard ... the "gold standard" treatment for HIV is known as ... a number of drugs that reduce viral load by ...
... America (HFA) announces the publication of Living ... addition to HFA,s Living With Grief(R) book series. ... is a compilation of chapters by well-known experts in grief ... end-of-life decision making, shapes attitudes around the experience of terminal ...
... Albert Einstein College of Medicine of Yeshiva University have proposed ... brains of people with autism are structurally normal but dysregulated, ... , The central tenet of the theory, published in the ... autism is a developmental disorder caused by impaired regulation of ...
... schizoaffective disorder who received paliperidone extended release tablets ... in a broad range of schizoaffective symptoms, according ... 12th International Congress on Schizophrenia Research (ICOSR) in ... provide additional evidence for symptomatic improvement of schizoaffective ...
... April 1st, Professional Healthcare Resources celebrates 15 years of ... The company was started in 1994 by Eileen DeCesare ... an organization offering home health, hospice, and personal care ... The company has over 700 employees and eight branch ...
Cached Medicine News:Health News:Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals 2Health News:New HIV Drug May Help Those Resistant to Therapy 2Health News:Hospice Foundation of America Publishes New Book on Diversity and End-of-Life Care 2Health News:Einstein scientists propose new theory of autism 2Health News:Einstein scientists propose new theory of autism 3Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 2Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 3Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 4Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 5Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 6Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 7Health News:Professional Healthcare Resources Celebrates 15 Year Anniversary 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: